Cargando…

Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?

Obesity is a major factor in contemporary clinical practice in nephrology. Obesity accelerates the progression of both diabetic and non-diabetic chronic kidney disease and, in renal transplantation, both recipient and donor obesity increase the risk of allograft complications. Obesity is thus a majo...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, William P., White, James, López-Hernández, Francisco J., Docherty, Neil G., le Roux, Carel W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462008/
https://www.ncbi.nlm.nih.gov/pubmed/33013677
http://dx.doi.org/10.3389/fendo.2020.00289
_version_ 1783576840401584128
author Martin, William P.
White, James
López-Hernández, Francisco J.
Docherty, Neil G.
le Roux, Carel W.
author_facet Martin, William P.
White, James
López-Hernández, Francisco J.
Docherty, Neil G.
le Roux, Carel W.
author_sort Martin, William P.
collection PubMed
description Obesity is a major factor in contemporary clinical practice in nephrology. Obesity accelerates the progression of both diabetic and non-diabetic chronic kidney disease and, in renal transplantation, both recipient and donor obesity increase the risk of allograft complications. Obesity is thus a major driver of renal disease progression and a barrier to deceased and living donor kidney transplantation. Large observational studies have highlighted that metabolic surgery reduces the incidence of albuminuria, slows chronic kidney disease progression, and reduces the incidence of end-stage kidney disease over extended follow-up in people with and without type 2 diabetes. The surgical treatment of obesity and its metabolic sequelae has therefore the potential to improve management of diabetic and non-diabetic chronic kidney disease and aid in the slowing of renal decline toward end-stage kidney disease. In the context of patients with end-stage kidney disease, although complications of metabolic surgery are higher, absolute event rates are low and it remains a safe intervention in this population. Pre-transplant metabolic surgery increases access to kidney transplantation in people with obesity and end-stage kidney disease. Metabolic surgery also improves management of metabolic complications post-kidney transplantation, including new-onset diabetes. Procedure selection may be critical to mitigate the risks of oxalate nephropathy and disruption to immunosuppressant pharmacokinetics. Metabolic surgery may also have a role in the treatment of donor obesity, which could increase the living kidney donor pool with potential downstream impact on kidney paired exchange programmes. The present paper provides a comprehensive coverage of the literature concerning renal outcomes in clinical studies of metabolic surgery and integrates findings from relevant mechanistic pre-clinical studies. In so doing the key unanswered questions for the field are brought to the fore for discussion.
format Online
Article
Text
id pubmed-7462008
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74620082020-10-01 Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions? Martin, William P. White, James López-Hernández, Francisco J. Docherty, Neil G. le Roux, Carel W. Front Endocrinol (Lausanne) Endocrinology Obesity is a major factor in contemporary clinical practice in nephrology. Obesity accelerates the progression of both diabetic and non-diabetic chronic kidney disease and, in renal transplantation, both recipient and donor obesity increase the risk of allograft complications. Obesity is thus a major driver of renal disease progression and a barrier to deceased and living donor kidney transplantation. Large observational studies have highlighted that metabolic surgery reduces the incidence of albuminuria, slows chronic kidney disease progression, and reduces the incidence of end-stage kidney disease over extended follow-up in people with and without type 2 diabetes. The surgical treatment of obesity and its metabolic sequelae has therefore the potential to improve management of diabetic and non-diabetic chronic kidney disease and aid in the slowing of renal decline toward end-stage kidney disease. In the context of patients with end-stage kidney disease, although complications of metabolic surgery are higher, absolute event rates are low and it remains a safe intervention in this population. Pre-transplant metabolic surgery increases access to kidney transplantation in people with obesity and end-stage kidney disease. Metabolic surgery also improves management of metabolic complications post-kidney transplantation, including new-onset diabetes. Procedure selection may be critical to mitigate the risks of oxalate nephropathy and disruption to immunosuppressant pharmacokinetics. Metabolic surgery may also have a role in the treatment of donor obesity, which could increase the living kidney donor pool with potential downstream impact on kidney paired exchange programmes. The present paper provides a comprehensive coverage of the literature concerning renal outcomes in clinical studies of metabolic surgery and integrates findings from relevant mechanistic pre-clinical studies. In so doing the key unanswered questions for the field are brought to the fore for discussion. Frontiers Media S.A. 2020-08-17 /pmc/articles/PMC7462008/ /pubmed/33013677 http://dx.doi.org/10.3389/fendo.2020.00289 Text en Copyright © 2020 Martin, White, López-Hernández, Docherty and le Roux. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Martin, William P.
White, James
López-Hernández, Francisco J.
Docherty, Neil G.
le Roux, Carel W.
Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?
title Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?
title_full Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?
title_fullStr Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?
title_full_unstemmed Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?
title_short Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?
title_sort metabolic surgery to treat obesity in diabetic kidney disease, chronic kidney disease, and end-stage kidney disease; what are the unanswered questions?
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462008/
https://www.ncbi.nlm.nih.gov/pubmed/33013677
http://dx.doi.org/10.3389/fendo.2020.00289
work_keys_str_mv AT martinwilliamp metabolicsurgerytotreatobesityindiabetickidneydiseasechronickidneydiseaseandendstagekidneydiseasewhataretheunansweredquestions
AT whitejames metabolicsurgerytotreatobesityindiabetickidneydiseasechronickidneydiseaseandendstagekidneydiseasewhataretheunansweredquestions
AT lopezhernandezfranciscoj metabolicsurgerytotreatobesityindiabetickidneydiseasechronickidneydiseaseandendstagekidneydiseasewhataretheunansweredquestions
AT dochertyneilg metabolicsurgerytotreatobesityindiabetickidneydiseasechronickidneydiseaseandendstagekidneydiseasewhataretheunansweredquestions
AT lerouxcarelw metabolicsurgerytotreatobesityindiabetickidneydiseasechronickidneydiseaseandendstagekidneydiseasewhataretheunansweredquestions